甲地孕酮联合化疗治疗晚期恶性肿瘤105例  

Clinical observation of megestrol acetate in combination with chemotherapy in advanced cancer: an analysis of 105 cases

作　　者：刘慧龙[1] 李红英[1] 阮新建[1] 王莉[1] 王飞[1] 刘彦芳[1] 

机构地区：[1]北京军区总医院肿瘤科,北京100700

出　　处：《中国新药杂志》2015年第12期1393-1396,共4页Chinese Journal of New Drugs

摘　　要：目的:评估甲地孕酮在晚期恶性肿瘤患者化疗期间的应用价值。方法:入组105例患者先接受1周期单独化疗,随后第2周期化疗开始前2 d连续应用甲地孕酮14 d,检测并分析患者两周期主要营养指标和恶心/呕吐的差异。结果:应用甲地孕酮后食欲改善率达到58.1%;KPS评分得到提升(79.0分vs76.0分,P=0.002);体重明显增加(60.7 kg vs 59.9 kg,P=0.016);血清白蛋白(36.7 g·L-1vs 35.9g·L-1,P=0.007)和血清前白蛋白(234.5 mg·L-1vs 221.7 mg·L-1,P=0.007)均有改善;但血红蛋白和恶心/呕吐无改善。KPS评分<80分患者多项指标改善更为显著。结论:甲地孕酮可以显著改善晚期恶性肿瘤患者化疗期间多项营养指标,减轻化疗对机体的不利影响,增加患者对化疗的耐受性和顺应性且安全性良好。Objective： To assess the value of megestrol acetate in advanced cancer when given around the chemotherapy. Methods： A total of 105 patients with advanced cancer received chemotherapy alone in the first cy- cle and combined megestrol acetate in the second cycle. Megestrol acetate was prescribed for 14 d and taken two days before the second cycle. Nutrition indices and symptoms of nausea/vomiting during the two different cycles were recorded and analyzed. Results： With the combination therapy of megestrol acetate, 58. 1% of patients showed an improvement in appetite. KPS score （79.0 vs. 76.0, P = 0. 002） , body weight （60.7 kg vs 59.9 kg, P=0.016）, serum albumin （36.7g·L-1 vs35.9g·L-1, P=0.007） and serum prealbumin （234.5 mg·L-1 vs 221.7 mg·L-1, P = 0. 007） were all improved significantly, but hemoglobin and symptoms of nausea/vomiting were unchanged. When compared with patients with high KPS score, the ones with low KPS score benefited more. Conclusion： Megestrol acetate can effectively improve the condition of nutrition and enhance adaptability and toler- ance for chemotherapy in advanced cancer patients with good safety.

关 键 词：甲地孕酮 化学治疗 晚期恶性肿瘤 营养状况 

分 类 号：R969[医药卫生—药理学]